PSMA PET Imaging of Recurrent Prostate Cancer (NCT03204123) | Clinical Trial Compass
Active — Not RecruitingPhase 2
PSMA PET Imaging of Recurrent Prostate Cancer
United States1,171 participantsStarted 2017-06-26
Plain-language summary
The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.
Who can participate
Age range18 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Biopsy proven adenocarcinoma of the prostate
* Initially treated with definitive local therapy (surgery and radiation therapy are the most common treatments, but other treatments are also eligible)
* For patients initially treated with surgery, radiation therapy, brachytherapy, or cryotherapy:
* PSA ≥ 0.2 ng/mL in at least two consecutive tests within 6 months of date of consent for patients
* Note: The most recent PSA value must be within 6 weeks of consent
* For patients who have received additional treatment in the recurrent or metastatic setting:
° PSA ≥ 2 ng/ml above the most recent therapy nadir
* Age ≥ 18 years
* Patient must be able to tolerate PET/CT or PET/MR imaging
Exclusion Criteria:
* Patient with claustrophobia that would preclude PET/CT or PET/MR imaging or other contraindications to CT imaging.